KIAA1429-mediated m6A modification of CHST11 promotes progression of diffuse large B-cell lymphoma by regulating Hippo–YAP pathway

Table 1 Correlation between KIAA1429 expression and clinical features of patients with DLBCL

Clinical variables	No. of patients	KIAA1429 expression		p value
Clinical variables	No. of patients	Positive	Negative	p value
Subtype
GCB	24	17 (70.8%)	7 (29.1%)	0.034*
Non-GCB	36	33 (91.7%)	3 (8.3%)	0.034*
Age (years)
< 60	28	24 (85.7%)	4 (14.3%)	0.643
≥ 60	32	26 (81.3%)	6 (18.7%)	0.643
Gender
Male	36	31 (86.1%)	5 (13.9%)	0.48
Female	24	19 (79.2%)	5 (20.8%)	0.48
Ann Arbor stage
I or II	20	13 (65%)	7 (35%)	0.007**
III or IV	40	37 (92.5%)	3 (7.5%)	0.007**
B symptoms
Present	10	9 (90%)	1 (10%)	0.535
Absent	50	41 (82%)	9 (18%)	0.535
Serum LDH
Normal	31	23 (72.2%)	8 (27.8%)	0.05
Elevated	29	27 (93.1%)	2 (6.9%)	0.05
Extranodal involvement
Present	55	46 (83.6%)	9 (16.4%)	0.853
Absent	5	4 (80%)	1 (20%)	0.853
IPI score
0–2	27	20 (74.1%)	7 (25.9%)	0.082
3–5	33	30 (90.9%)	3 (9.1%)	0.082

The bold values mean statistically significant
GCB germinal center B cell-like, LDH lactate dehydrogenase, IPI International Prognostic Index
*p < 0.05, **p < 0.01

ISSN: 1689-1392